| Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 AV Krivtsov, D Twomey, Z Feng, MC Stubbs, Y Wang, J Faber, JE Levine, ... Nature 442 (7104), 818-822, 2006 | 1786 | 2006 |
| MLL translocations, histone modifications and leukaemia stem-cell development AV Krivtsov, SA Armstrong Nature reviews cancer 7 (11), 823-833, 2007 | 1423 | 2007 |
| MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L KM Bernt, N Zhu, AU Sinha, S Vempati, J Faber, AV Krivtsov, Z Feng, ... Cancer cell 20 (1), 66-78, 2011 | 943 | 2011 |
| The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML Y Wang, AV Krivtsov, AU Sinha, TE North, W Goessling, Z Feng, LI Zon, ... Science 327 (5973), 1650-1653, 2010 | 891 | 2010 |
| H3K79 methylation profiles define murine and human MLL-AF4 leukemias AV Krivtsov, Z Feng, ME Lemieux, J Faber, S Vempati, AU Sinha, X Xia, ... Cancer cell 14 (5), 355-368, 2008 | 617 | 2008 |
| HOXA9 is required for survival in human MLL-rearranged acute leukemias J Faber, AV Krivtsov, MC Stubbs, R Wright, TN Davis, ... Blood, The Journal of the American Society of Hematology 113 (11), 2375-2385, 2009 | 386 | 2009 |
| The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia EM Stein, G Garcia-Manero, DA Rizzieri, R Tibes, JG Berdeja, ... Blood, The Journal of the American Society of Hematology 131 (24), 2661-2669, 2018 | 370 | 2018 |
| Mediator kinase inhibition further activates super-enhancer-associated genes in AML HE Pelish, BB Liau, II Nitulescu, A Tangpeerachaikul, ZC Poss, ... Nature 526 (7572), 273-276, 2015 | 359 | 2015 |
| Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins SCW Lee, H Dvinge, E Kim, H Cho, JB Micol, YR Chung, BH Durham, ... Nature medicine 22 (6), 672-678, 2016 | 358 | 2016 |
| Loss of BAP1 function leads to EZH2-dependent transformation LM LaFave, W Béguelin, R Koche, M Teater, B Spitzer, A Chramiec, ... Nature medicine 21 (11), 1344-1349, 2015 | 353 | 2015 |
| A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies S Boettcher, PG Miller, R Sharma, M McConkey, M Leventhal, AV Krivtsov, ... Science 365 (6453), 599-604, 2019 | 304 | 2019 |
| A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia AV Krivtsov, K Evans, JY Gadrey, BK Eschle, C Hatton, HJ Uckelmann, ... Cancer cell 36 (6), 660-673. e11, 2019 | 263 | 2019 |
| DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling OA Guryanova, K Shank, B Spitzer, L Luciani, RP Koche, ... Nature medicine 22 (12), 1488-1495, 2016 | 240 | 2016 |
| Cell of origin determines clinically relevant subtypes of MLL-rearranged AML AV Krivtsov, ME Figueroa, AU Sinha, MC Stubbs, Z Feng, PJM Valk, ... Leukemia 27 (4), 852-860, 2013 | 222 | 2013 |
| Requirement for CDK6 in MLL-rearranged acute myeloid leukemia T Placke, K Faber, A Nonami, SL Putwain, HR Salih, FH Heidel, A Krämer, ... Blood, The Journal of the American Society of Hematology 124 (1), 13-23, 2014 | 211 | 2014 |
| A UTX-MLL4-p300 transcriptional regulatory network coordinately shapes active enhancer landscapes for eliciting transcription SP Wang, Z Tang, CW Chen, M Shimada, RP Koche, LH Wang, ... Molecular cell 67 (2), 308-321. e6, 2017 | 204 | 2017 |
| AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes AJ Deshpande, A Deshpande, AU Sinha, L Chen, J Chang, A Cihan, ... Cancer cell 26 (6), 896-908, 2014 | 181 | 2014 |
| TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells N Verma, H Pan, LC Doré, A Shukla, QV Li, B Pelham-Webb, V Teijeiro, ... Nature genetics 50 (1), 83-95, 2018 | 173 | 2018 |
| Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia HJ Uckelmann, SM Kim, EM Wong, C Hatton, H Giovinazzo, JY Gadrey, ... Science 367 (6477), 586-590, 2020 | 169 | 2020 |
| MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment MC Stubbs, YM Kim, AV Krivtsov, RD Wright, Z Feng, J Agarwal, AL Kung, ... Leukemia 22 (1), 66-77, 2008 | 152 | 2008 |
Amit U SinhaInstructor, Dana-Farber Cancer Inst and Harvard Medical SchoolDirección de correo verificada de dfci.harvard.edu
